Q-omics provides the consensus-scored WNT5B profile across patient tissues and cancer cell-line models. WNT5B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, WNT5B is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, WNT5B protein abundance shows 27,131 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, and LUAD as cancer lineages where WNT5B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WNT5B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WNT5B survival associations across molecular data types. WNT5B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WNT5B RNA expression–survival associations across cancer types. High WNT5B expression shows unfavorable associations in MESO and SARC, but favorable associations in ACC, LIHC, LGG and THYM. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for WNT5B RNA expression.
This table summarizes WNT5B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for WNT5B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WNT5B shows lower tumor expression in BLCA, UCEC and BRCA and higher tumor expression in LUAD, LUSC and KIRP. The LUAD box plot shows higher WNT5B RNA expression in tumor versus normal tissue (log2 FC = +0.806, t-test p < 0.001).
This table shows molecular features associated with WNT5B in patient tissues and cancer cell lines. In patient samples, WNT5B shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, WNT5B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
